etrumadenant + zimberelimab + docetaxel

**Etrumadenant + zimberelimab + docetaxel** is an investigational multi-agent combination for solid tumors, especially advanced or metastatic colorectal cancer. It consists of: - **Etrumadenant:** a selective, orally bioavailable small molecule dual antagonist of the A2a and A2b adenosine receptors, designed to disrupt adenosine-mediated immunosuppression within the tumor microenvironment, thus promoting anti-tumor immune responses. - **Zimberelimab:** a monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor, blocking its inhibitory effect on T cells and restoring anti-tumor immunity. - **Docetaxel:** a well-established taxane chemotherapeutic that stabilizes microtubules and inhibits cell division, leading to cancer cell death. Combined, these agents are evaluated to overcome multi-factorial resistance mechanisms in cancer by using immunomodulation (etrumadenant and zimberelimab) together with cytotoxic chemotherapy (docetaxel). The combination is being studied primarily in metastatic colorectal cancer, showing a significant survival benefit in Phase 1b/2 (ARC-9) but has not progressed to Phase 3 trials as of mid-2024[1][2][4].